These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12010992)

  • 1. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.
    Beignon AS; Briand JP; Rappuoli R; Muller S; Partidos CD
    Infect Immun; 2002 Jun; 70(6):3012-9. PubMed ID: 12010992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
    Beignon AS; Briand JP; Muller S; Partidos CD
    Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
    Tierney R; Beignon AS; Rappuoli R; Muller S; Sesardic D; Partidos CD
    J Infect Dis; 2003 Sep; 188(5):753-8. PubMed ID: 12934192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55.
    Neidleman JA; Vajdy M; Ugozzoli M; Ott G; O'Hagan D
    Immunology; 2000 Sep; 101(1):154-60. PubMed ID: 11012767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides.
    Partidos CD; Salani BF; Pizza M; Rappuoli R
    Immunol Lett; 1999 Apr; 67(3):209-16. PubMed ID: 10369128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.
    Erume J; Partidos CD
    Afr Health Sci; 2011 Jun; 11(2):151-7. PubMed ID: 21857843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
    Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
    J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
    De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
    Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.
    Bonenfant C; Dimier-Poisson I; Velge-Roussel F; Buzoni-Gatel D; Del Giudice G; Rappuoli R; Bout D
    Infect Immun; 2001 Mar; 69(3):1605-12. PubMed ID: 11179334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity.
    Giuliani MM; Del Giudice G; Giannelli V; Dougan G; Douce G; Rappuoli R; Pizza M
    J Exp Med; 1998 Apr; 187(7):1123-32. PubMed ID: 9529328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production.
    Brereton CF; Sutton CE; Ross PJ; Iwakura Y; Pizza M; Rappuoli R; Lavelle EC; Mills KH
    J Immunol; 2011 May; 186(10):5896-906. PubMed ID: 21490151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit.
    de Haan L; Verweij WR; Feil IK; Holtrop M; Hol WG; Agsteribbe E; Wilschut J
    Immunology; 1998 Jul; 94(3):424-30. PubMed ID: 9767427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.
    Peppoloni S; Ruggiero P; Contorni M; Morandi M; Pizza M; Rappuoli R; Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):285-93. PubMed ID: 12899578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
    Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
    J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
    Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
    Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.